72 related articles for article (PubMed ID: 3065224)
21. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
[TBL] [Abstract][Full Text] [Related]
22. [History of clinical studies on hypothalamic hormone analogs in Mexico].
Schally AV; González Bárcena D
Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307
[TBL] [Abstract][Full Text] [Related]
23. Hypothalamic hormones and cancer.
Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G
Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553
[TBL] [Abstract][Full Text] [Related]
24. [Developments in endocrine therapy for breast cancer].
Matsui A; Ikeda T; Jinno H; Tajima G; Hohjou T; Tokura H; Mitsui Y; Asaga S; Muto T; Kitajima M
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1138-45. PubMed ID: 12145993
[TBL] [Abstract][Full Text] [Related]
25. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
26. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
Prowell TM; Davidson NE
Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
[TBL] [Abstract][Full Text] [Related]
27. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
[TBL] [Abstract][Full Text] [Related]
28. Gonadotropin-releasing hormone analogues alter gene expression of metalloproteinases and their tissue inhibitors in human breast cancer epithelial cells.
Lamari FN; Zompra AA; Pateraki E; Kousidou OC; Magafa V; Karamanos NK; Cordopatis P
Anticancer Res; 2006; 26(6B):4615-21. PubMed ID: 17201186
[TBL] [Abstract][Full Text] [Related]
29. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
[TBL] [Abstract][Full Text] [Related]
30. Chemoprevention of breast cancer.
Bonte J
Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():141-5. PubMed ID: 8298444
[No Abstract] [Full Text] [Related]
31. Influence of LH-RH agonists and antagonists on gonadotropin release in humans.
González-Bárcena D; Ortíz HT; Gordon F; Kastin AJ; Coy D; Schally AV
Int J Fertil; 1980; 25(3):185-9. PubMed ID: 6108927
[No Abstract] [Full Text] [Related]
32. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
33. [Anthology of the first clinical studies with hypothalamic hormones: a story of successful international cooperation].
Schally AV; Gual C
Gac Med Mex; 2002; 138(1):89-100. PubMed ID: 11885134
[TBL] [Abstract][Full Text] [Related]
34. Ovarian ablation as treatment for young women with breast cancer.
Davidson NE
J Natl Cancer Inst Monogr; 1994; (16):95-9. PubMed ID: 7528032
[TBL] [Abstract][Full Text] [Related]
35. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
[TBL] [Abstract][Full Text] [Related]
36. New endocrine approaches in the treatment of breast cancer.
von Minckwitz G; Kaufmann M
Biomed Pharmacother; 1998; 52(3):122-32. PubMed ID: 9755805
[TBL] [Abstract][Full Text] [Related]
37. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
[TBL] [Abstract][Full Text] [Related]
38. New approaches to the therapy of various tumors based on peptide analogues.
Schally AV
Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
[TBL] [Abstract][Full Text] [Related]
39. [Effectiveness of LH-RH agonist for bone metastases of breast cancer--report of a case].
Kudoh S; Kawamura H; Suzuki Y; Matsuzaki M; Nishina M; Tsukamoto M
Gan To Kagaku Ryoho; 1996 May; 23(6):787-90. PubMed ID: 8645031
[TBL] [Abstract][Full Text] [Related]
40. LHRH analogues and breast cancer.
Korkut E; Comaru-Schally AM; Schally AV; Plowman PN
Br J Cancer; 1991 Dec; 64(6):1190. PubMed ID: 1764388
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
